Return-Path: <01070195513ed031-ac5dd931-01ff-4215-86c3-6388247926be-000000@eu-central-1.amazonses.com> Delivered-To: aburayhan@banglamarkgroup.com Received: from server2.www.flokoin.com by server2.www.flokoin.com with LMTP id GOvfKyXhwmc2nR4AB2Lfrw (envelope-from <01070195513ed031-ac5dd931-01ff-4215-86c3-6388247926be-000000@eu-central-1.amazonses.com>) for ; Sat, 01 Mar 2025 10:27:49 +0000 Return-path: <01070195513ed031-ac5dd931-01ff-4215-86c3-6388247926be-000000@eu-central-1.amazonses.com> Envelope-to: aburayhan@banglamarkgroup.com Delivery-date: Sat, 01 Mar 2025 10:27:49 +0000 Received: from b224-123.smtp-out.eu-central-1.amazonses.com ([69.169.224.123]:53919) by server2.www.flokoin.com with esmtps (TLS1.3) tls TLS_AES_128_GCM_SHA256 (Exim 4.98.1) (envelope-from <01070195513ed031-ac5dd931-01ff-4215-86c3-6388247926be-000000@eu-central-1.amazonses.com>) id 1toK4T-00000008Ptz-2Wk5 for aburayhan@banglamarkgroup.com; Sat, 01 Mar 2025 10:27:49 +0000 DKIM-Signature: v=1; a=rsa-sha256; q=dns/txt; c=relaxed/simple; s=agndqi7w2t7yolnid2varbfr2q7hw6j3; d=follow.it; t=1740824826; h=Message-ID:Date:Subject:From:Reply-To:To:MIME-Version:Content-Type:Content-Transfer-Encoding:List-Unsubscribe-Post:List-Unsubscribe; bh=Sje3Xn0aV4SuEJgWGNazLi0cY88O9h4NkdCykqFzUE0=; b=UR3aU4IPSMhWgtP9xdeNnEL+wbJMiKRD3KEcy/pYaqlxOGkUxDgOaQjQoxSiZ3vq 0B0QBv396HPz06Gd9gH0AO7nQZrj4Fbjmfl2wRq4hJ38N9v5FuMJYNGon1Uq9jrUZqE 8VFUuo3FiaW5bjO4T2lUBljnLHdk0IskUzkX0zoY= DKIM-Signature: v=1; a=rsa-sha256; q=dns/txt; c=relaxed/simple; s=54ecsf3zk7z4mwxwwox7z7bg6e5gwjsz; d=amazonses.com; t=1740824826; h=Message-ID:Date:Subject:From:Reply-To:To:MIME-Version:Content-Type:Content-Transfer-Encoding:List-Unsubscribe-Post:List-Unsubscribe:Feedback-ID; bh=Sje3Xn0aV4SuEJgWGNazLi0cY88O9h4NkdCykqFzUE0=; b=uRqJAZjuFChcgw3iXvo8bFOcDprTg4D3GUJQTW34YaO5RISnV5aoackVsvaFVkXH 0opHpnJ2ONWyjXsINOq7UmzmMoHT1I4dJh4aOq8DiMfe6rzF8dHXiqa8cYDkD+kbcA4 wjMG1JuwmjNKTZkArkIa5KAeOT3LA6huPFGIMX84= Message-ID: <01070195513ed031-ac5dd931-01ff-4215-86c3-6388247926be-000000@eu-central-1.amazonses.com> Date: Sat, 1 Mar 2025 10:27:05 +0000 Subject: Preparation of Master Formula Record (MFR) From: Pharmaguideline Reply-To: info@pharmaguideline.com To: aburayhan@banglamarkgroup.com MIME-Version: 1.0 Content-Type: text/html; charset=utf-8 Content-Transfer-Encoding: quoted-printable X-userID: 14167572 Original-Message-ID: ZXenaMapl34jjpX2kBX6S@follow.it List-Unsubscribe-Post: List-Unsubscribe=One-Click List-Unsubscribe: Feedback-ID: ::1.eu-central-1.WaaZLhzS7OXYfx9SJWPqRineKdQSbFPcc60C9v9ZUc0=:AmazonSES X-SES-Outgoing: 2025.03.01-69.169.224.123 X-Spam-Status: No, score=0.0 X-Spam-Score: 0 X-Spam-Bar: / X-Ham-Report: Spam detection software, running on the system "server2.www.flokoin.com", has NOT identified this incoming email as spam. The original message has been attached to this so you can view it or label similar future email. If you have any questions, see root\@localhost for details. Content preview: Newspaper - You subscribed to receive the contents below, but haven't confirmed it yet. Please confirm your subscription by clicking here or report that you don't want to receive it. Pharmaguideline Edit Prepa [...] Content analysis details: (0.0 points, 5.0 required) pts rule name description ---- ---------------------- -------------------------------------------------- 0.0 URIBL_BLOCKED ADMINISTRATOR NOTICE: The query to URIBL was blocked. See http://wiki.apache.org/spamassassin/DnsBlocklists#dnsbl-block for more information. [URI: whatsapp.com] [URI: pharmaguideline.com] [URI: follow.it] 0.0 RCVD_IN_VALIDITY_SAFE_BLOCKED RBL: ADMINISTRATOR NOTICE: The query to Validity was blocked. See https://knowledge.validity.com/hc/en-us/articles/20961730681243 for more information. [69.169.224.123 listed in sa-accredit.habeas.com] 0.0 RCVD_IN_VALIDITY_RPBL_BLOCKED RBL: ADMINISTRATOR NOTICE: The query to Validity was blocked. See https://knowledge.validity.com/hc/en-us/articles/20961730681243 for more information. [69.169.224.123 listed in bl.score.senderscore.com] 0.0 RCVD_IN_VALIDITY_CERTIFIED_BLOCKED RBL: ADMINISTRATOR NOTICE: The query to Validity was blocked. See https://knowledge.validity.com/hc/en-us/articles/20961730681243 for more information. [69.169.224.123 listed in sa-trusted.bondedsender.org] -0.0 SPF_HELO_PASS SPF: HELO matches SPF record -0.0 SPF_PASS SPF: sender matches SPF record 0.1 DKIM_SIGNED Message has a DKIM or DK signature, not necessarily valid -0.1 DKIM_VALID_AU Message has a valid DKIM or DK signature from author's domain -0.1 DKIM_VALID Message has at least one valid DKIM or DK signature 0.0 HEADER_FROM_DIFFERENT_DOMAINS From and EnvelopeFrom 2nd level mail domains are different 0.0 HTML_FONT_LOW_CONTRAST BODY: HTML font color similar or identical to background 0.0 HTML_MESSAGE BODY: HTML included in message 0.1 MIME_HTML_ONLY BODY: Message only has text/html MIME parts 0.0 T_KAM_HTML_FONT_INVALID Test for Invalidly Named or Formatted Colors in HTML X-Spam-Flag: NO Newspaper = =
=
= =20 =20 = = =20 =20 =
3D"Pharmaguideline"
You subscribed to receive the contents below, but = haven't confirmed it yet. Please confirm your subscription by clicking here or report tha= t you don't want to recei= ve it.
= = =
= =20 = =
= <= tr> =
= = = = =
= = =3D"Pharmaguideline" = =
=
= <= tr> = = =20 =20 = = = = =
Ph= armaguideline = = = = = =
= = Edit =
=
= = = = = = = = = = = = = =
= = Preparation of Mas= ter Formula Record (MFR) = =
= = Mar 1, 2025 =
=

Master formula record (MFR) is a master document for any pharmaceutica= l product. It contains all information about the manufacturing process for = the product. MFR is prepared by the research and development team of the co= mpany and all other documents like BMR and BPR are prepared using MFR by th= e manufacturing units. A MFR should have followin= g parts: 1. Product Details: First of all

=
= = = = = = = =
= = Continue Reading = = = 3D"" = =
=
=
=
= = = =
=

=F0=9F=9A=80 Advance Yo= ur Pharmaceutical Career!

Enhance your expertise with&nbs= p;industry-recognized certific= ations from Pharmaguideline. Learn from experts, gain practical= skills, and stand out in the competitive pharmaceutical industry.

= =F0=9F=92=A1Course 1: The Ultimate Guide to Good Manufacturing Practi= ces

=F0=9F=92=A1Course 2: Guide to Effective CAPA Management

= =F0=9F=92=A1Course 3: Step-by-Step Guide to Analytical Method Validation<= /a>


Why Choose Pharma= guideline?

=E2=9C=85 Expert-Led Online Courses

= =E2=9C=85 Certificates with Scores

=E2=9C=85 100% Money-Back Guaran= tee

=E2=9C=85 Flexible & Self-Paced Learning


=F0=9F=8E=AF Who Will Benefit?=

=F0=9F=93=8C Pharmaceutical Industry Professionals

= =F0=9F=93=8C Quality Assurance & Control Experts

=F0=9F=93= =8C Regulatory & Compliance Specialists

=F0=9F=93=8C Pharmacy S= tudents & Graduates


=F0=9F=94=A5 Limited-Time Offer (50%= OFF) =E2=80=93 Enroll Now! =F0=9F=94=A5

=

=F0=9F=93=9A Start L= earning Today: https://www.pharma= guideline.com/p/courses.html

=F0=9F=92=AC Have question= s? Contact us at courses@pharmaguideline.co= m or Whatsapp

=
= =
=
= =
= = = =
= =
=
=
This= email was sent by follow.it. = However, the contents of this em= ail are provided by the publisher of the feeds you are following. = follow.it is not affiliated with those publishers i= n any way nor do we take any responsibility for their content. If you want = to report content which does not adhere to our = Terms of Use please = contact us.
= = To unsubscribe from the feed, click here. =
= Pharmaguideline | E449/2, Hardevpuri | Shahdara | New = Delhi | India
=
=